Clinical Trial Update: A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of D3L-001 as monotherapy in HER2-positive advanced solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• D3L-001

Snippet

Sponsor: D3 Bio (Wuxi) Co., Ltd | Conditions: HER-2 Positive Advanced Solid Tumors | Phase 1 | Status: RECRUITING